Table 3: Response to tyrisine kinase (i.e. imatinib mesylate) in patients with myeloid neoplasms associated with ETV6-PDGFRB rearrangement.
|Study||Male/Female||ETV6-PDGFRB patients/Other PDGFR rearrangements||Tyrosine kinase (i.e. imatinib mesylate) Dosage regimen||Response to treatment|
|Apperley, et al. ||4/0||4/0||From 400 to 800 mg/daily||No residual disease at 9 to 12 months after the initiation of the treatment|
|David, et al. ||10/2||8/4||From 200 to 800 mg/daily||Hematological response: 49 months (19-60 months)
Cytogenetic response: 47 months (16-59 months)
10 patients were still alive at the time of publication (including all ETV6-PDGFRB patients)
|Arefi, et al. ||8/2||2/8||400 mg/daily||7 patients achived complete cytologic and hematological reponse including both ETV6-PDGFRB patients - median follow-up = 19 months|